Bristol Myers Squibb (BMY)

[Johnny_C]

Interesting trading.... mostly all red except Pfe and BMY. BIIB lost all its hyped up gain from Barron’s pump and then some.

BMY up on pathetic volume, tax reform votes about to start and PFE should have bids on consumer division.

December could be a great month for deals.

If it is BMY, and that has been the rumor since Febuary, premium to pps has been guessed at anywhere from 20 percent to $100 a share.

If it is Biogen I? haven’t seen any estimates. Historical premiums for mega deal pharma deals average is plus 30 percent.

Either way, PFE could also make a good move.

Trouble with Barron’s article regarding PFE finding BIIB more attractive due to Alzheimers is BIIB drug has a long way to go and they have come up short before. While Opdivo is proven and likely to have many more successful indications.

Pfe has missed twice with mega mergers, Allergan and Astra ( twice with Astra)

In any event, BMY seems a pretty good buy at these share prices.